



Further clinical results from the use of Episealer® to be presented at the annual meeting of the German Knee Society

Episurf Medical (NASDAQ: EPIS B) today announces that the scientific abstract "Clinical 2 years results after implantation of patient-specific mini-metal implants in middle-aged patients after previous frustane cartilage surgery" by Priv.-Doz. Dr. med. Clemens Kösters has been accepted for presentation at the 7th Annual Congress of the Deutschen Kriegesellschaft (DKG, the German Knee Society). The congress will take place in Munich on November 23-24, 2018. The abstract focuses on patients treated with the Episealer® knee implant after previously failed cartilage surgery. The results will be presented by Priv.-Doz. Dr. med. Clemens Kösters from Maria-Josef-Hospital in Greven, Germany.

"Patients who have been through cartilage surgery and failed constitute a large patient population worldwide. We are very happy that this presentation from Priv.-Doz. Dr. med. Clemens Kösters, focusing on this patient group, has been accepted for this important meeting," says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

*Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical's Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's *μ*Fidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.*